Secondary prevention after CABG: do new agents change the paradigm?
Amélie Paquin1,2, Paul Poirier1,3, Jonathan Beaudoin1,2
1Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval.
Insights
Coronary artery bypass graft (CABG) surgery patients face risks of recurrent events. Novel therapies targeting inflammation, metabolism, and clotting show promise for secondary prevention after CABG.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Background:
- Coronary artery bypass graft (CABG) surgery is the standard for complex coronary artery disease.
- Despite CABG success, patients experience residual risks of ischemic events and other cardiovascular outcomes.
- Secondary prevention is crucial for managing long-term outcomes post-CABG.
Purpose of the Study:
- To review recent evidence on pharmacological preventive therapies for residual cardiovascular risk in CABG patients.
- To summarize novel strategies targeting inflammatory, metabolic, and prothrombotic pathways.
- To assess the role of enhanced therapies in secondary prevention after CABG.
Main Methods:
- Literature review of recent studies on pharmacological interventions.
- Analysis of evidence for novel lipid-lowering and glucose-controlling agents.
- Evaluation of antiplatelet, anticoagulation, and other modulating therapies.
Main Results:
- Novel pharmacological strategies show promising results for secondary prevention post-CABG.
- Lipid-lowering and glucose-controlling agents demonstrate consistent benefits for native coronary artery disease and overall outcomes.
- Emerging therapies target inflammatory, metabolic, and prothrombotic pathways.
Conclusions:
- Secondary prevention is vital after CABG, with novel agents offering significant benefits.
- Further research is needed to define optimal enhanced therapies and identify new targets for graft disease.
- Long-term graft patency and multifactorial graft disease require dedicated preventive strategies.
Purpose Of Review:
Coronary artery bypass graft (CABG) surgery remains the gold-standard treatment for multivessel and left main coronary artery disease. Despite significant improvement in cardiovascular outcomes, patients undergoing CABG remain at risk for recurrent adverse ischemic events and other cardiovascular outcomes (coronary revascularisation, stroke, cardiac death, etc.). The purpose of this review is to summarize the most recent evidence in pharmacological preventive therapies addressing the residual cardiovascular risk in patients who have undergone CABG.
Recent Findings:
Novel cardiovascular pharmacological preventive strategies targeting inflammatory, metabolic and prothrombotic (antiplatelet and anticoagulation) pathways have been recently assessed, with promising results for secondary prevention after CABG.
Summary:
Secondary prevention is an essential part of postoperative care after CABG. Novel lipid-lowering and glucose-controlling agents suggest a strong and consistent benefit on native coronary artery disease and overall cardiovascular outcomes. The role and the choice of enhanced antiplatelet/anticoagulation/lipid/glucose-modulating therapies following CABG should be better defined and deserves further investigation. Additional studies are required to identify new therapeutic target addressing the specific multifactorial nature of the graft CV disease and identifying the best preventive strategies for long-term graft patency.
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease IV: Preventive Measures
Acute Coronary Syndrome IV: Interprofessional Care
Atherosclerosis III: Management
Peripheral Artery Disease V: Postoperative Nursing Management


